This was confirmed in a recent composite analysis study with 366 subjects, where GBA mutation carriers that were treated with STN-DBS showed faster cognitive decline than GBA carriers with no DBS (Mattis Dementia rating Scale decline 1.71 points/year more), and even more so than noncarriers treated with DBS (Mattis Dementia rating Scale decline 1.49 points/year more; Pal et al., 2022). The gene discussed is GBA1; the disease is dementia.